A Phase III Multicenter Randomized Double-Blind Double-Dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple sclerosis (Operetta 2)

Brief description of study

The study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with Relapsing-Remitting Multiple sclerosis (RRMS) The purpose of this research is to compare the effects, good or bad, of the study drug ocrelizumab versus fingolimod. Fingolimod is a medicine used for the treatment of patients aged 10 years and older with RRMS. Ocrelizumab is an experimental drug for children and adolescents.

Clinical Study Identifier: s21-00603
ClinicalTrials.gov Identifier: NCT04853251

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.